News
SGFEF
730.00
NaN%
--
Siegfried’s DINAMIQS Opens Switzerland’s First cGMP Viral Vector Facility
TipRanks · 09/29 05:02
Siegfried Holding AG (SGFEF) Receives a Buy from UBS
TipRanks · 09/28 11:35
Siegfried Holding AG Announces Leadership Transition
TipRanks · 09/26 05:02
Siegfried initiated with a Hold at Kepler Cheuvreux
TipRanks · 09/24 09:20
Weekly Report: what happened at SGFEF last week (0908-0912)?
Weekly Report · 09/15 10:59
Siegfried AG Secures CHF 300 Million in Bond Placement
TipRanks · 09/11 05:03
Siegfried initiated with an Outperform at William Blair
TipRanks · 09/09 11:16
Weekly Report: what happened at SGFEF last week (0901-0905)?
Weekly Report · 09/08 11:00
Stifel Nicolaus Reaffirms Their Hold Rating on Siegfried Holding AG (SGFEF)
TipRanks · 09/05 13:38
Siegfried upgraded to Outperform from Sector Perform at RBC Capital
TipRanks · 09/03 08:30
RBC Capital upgrades Siegfried Holding AG (SGFEF) to a Buy
TipRanks · 09/03 06:25
Weekly Report: what happened at SGFEF last week (0825-0829)?
Weekly Report · 09/01 10:57
Weekly Report: what happened at SGFEF last week (0818-0822)?
Weekly Report · 08/25 11:06
UBS Sticks to Their Buy Rating for Siegfried Holding AG (SGFEF)
TipRanks · 08/22 09:15
Siegfried Holding AG Reports Stable Half-Year Performance
TipRanks · 08/22 04:02
Siegfried Holding AG Reports Profitable Growth and Strategic Expansions in H1 2025
TipRanks · 08/21 05:02
Weekly Report: what happened at SGFEF last week (0811-0815)?
Weekly Report · 08/18 10:59
Weekly Report: what happened at SGFEF last week (0804-0808)?
Weekly Report · 08/11 11:05
Weekly Report: what happened at SGFEF last week (0728-0801)?
Weekly Report · 08/04 11:08
Weekly Report: what happened at SGFEF last week (0721-0725)?
Weekly Report · 07/28 11:09
More
Webull provides a variety of real-time SGFEF stock news. You can receive the latest news about Siegfried Hldg Ltd through multiple platforms. This information may help you make smarter investment decisions.
About SGFEF
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.